Homeopathic drug proving of Okoubaka aubrevillei: A randomised placebo-controlled trial

Trials

Volumn 14, Issue 1, 2013, Pages

  Teut, Michael ^a   Dahler, Joern ^a   Hirschberg, Ute ^a   Luedtke, Rainer ^b   Albrecht, Henning ^b   Witt, Claudia M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Karl and Veronica Carstens Foundation   (Germany)

Author keywords

Homeopathic drug proving; Homeopathic pathogenetic trial; Okoubaka aubrevillei

Indexed keywords

HOMEOPATHIC AGENT; OKOUBAKA AUBREVILLEI; PLACEBO; SUCROSE; UNCLASSIFIED DRUG; MATERIA MEDICA;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG POTENCY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SEX DIFFERENCE; TREATMENT OUTCOME; CLINICAL TRIAL; GERMANY; HOMEOPATHY; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; NOCEBO EFFECT; PROCEDURES; RISK; TIME;

ADULT; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HOMEOPATHY; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MATERIA MEDICA; MIDDLE AGED; NOCEBO EFFECT; ODDS RATIO; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875826835     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-96     Document Type: Article

References (32)

1. Dantas F, Fisher P, Walach H, Wieland F, Rastogi DP, Texeira H, Koster D, Jansen JP, Eizayaga J, Alvarez MEP, Marim M, Belon P, Weckx LLM. A systematic review of the quality of homeopathic pathogenetic trials published from 1945 to 1995. Homeopathy 2007, 96:4-16. 10.1016/j.homp.2006.11.005, 17227742.
2. European Committee for Homeopathy Homeopathic drug proving guidelines 2004, Brussels, [http://www.homeopathyeurope.org/downloads/ECH_Proving_Guidelines_v1.pdf], European Committee for Homeopathy.
3. Teut M, Dahler J, Lucae C, Koch U. Kursbuch Homöopathie 2008, München: Urban und Fischer.
4. Walach H. Methoden der Homöopathischen Arzneimittelprüfung, Teil 1: Historische Entwicklung und Stand der Forschung. Naturheilverfahren und Unkonventionelle Medizinische Richtungen. Bd. 4 2005, Berlin/Heidelberg: Springer, Bühring M, Kemper FH.
5. Hahnemann S. Organon der Heilkunst. Textkritische Ausgabe. 1999, Stuttgart: Haug Publishers, Schmidt JM.
6. Walach H. Wissenschaftliche Homöopathische Arzneimittelprüfung. Doppelblinde Crossover-Studie einer homöopathischen Hochpotenz gegen Placebo 1992, Heidelberg: Haug.
7. Möllinger H, Schneider R, Löffel M, Walach H. A double-blind, randomised, homeopathic pathogenetic trial with healthy persons: comparing two high potencies. Forsch Komplementarmed Klass Naturheilkd 2004, 11:274-280. 10.1159/000082120, 15572868.
8. Walach H, Sherr J, Schneider R, Shabi R, Bond G, Rieberer G. Homeopathic proving symptoms: result of a local, non-local, or placebo-process? A blinded, placebo-controlled pilot study. Homeopathy 2004, 93:179-185. 10.1016/j.homp.2004.07.006, 15532695.
9. Möllinger H, Schneider R, Walach H. Homeopathic pathogenetic trials produce specific symptoms different from placebo. Forsch Komplementarmed 2009, 16:105-110.
10. Walach H, Möllinger H, Sherr J, Schneider R. Homeopathic pathogenetic trials produce more specific than non-specific symptoms: results from two double-blind placebo controlled trials. J Psychopharmacol 2008, 22:543-552. 10.1177/0269881108091259, 18701641.
11. Teut M, Dahler J, Schnegg C, Wilsede Study Group for Homeopathic Provings A homeopathic proving of Galphimia glauca. Forsch Komplementarmed 2008, 15:211-217. Wilsede Study Group for Homeopathic Provings.
12. Teut M, Hirschberg U, Luedtke R, Schnegg C, Dahler J, Albrecht H, Witt CM. Protocol for a phase 1 homeopathic drug proving trial. Trials 2010, 11:80. 10.1186/1745-6215-11-80, 2917434, 20649979.
13. Homöopathisches Arzneibuch 2009 (HAB 2009). Amtliche Ausgabe 2009, Stuttgart: Deutscher Apotheker Verlag.
14. Mayring P. Qualitative Inhaltsanalyse. Grundlagen und Techniken. 7. Auflage 2000, Weinheim: Deutscher Studien Verlag.
15. Rubin DB. Multiple Imputations for Nonresponse in Surveys 1987, New York: John Wiley & Sons.
16. Kunst M. Okoubaka, ein neues homöopathisches Arzneimittel. AHZ 1972, 3:116-121.
17. Wagner H, Kreutzkamp B, Jurcic K. Inhaltsstoffe und Pharmakologie der Okoubaka aubrevillei-Rinde. Planta Med 1985, 5:404-407.
18. Schlüren E. Okoubaka aubrevillei - ein klinischer Erfahrungsbericht. AHZ 1991, 236:225-231.
19. Boericke W. Homöopathische Mittel und ihre Wirkungen. Materia Medica und Repertorium 2008, Leer: Grundlagen und Praxis Wissenschaftlicher Autorenverlag, 9.
20. Riley DS. Materia Medica of New and Old Homeopathic Medicines 2012, Berlin Heidelberg: Springer Verlag.
21. Stübler M. Die Arzneimittelprüfung am gesunden Menschen. Geschichte und Aufbau der heutigen Prüfungsmethoden in der Homöopathie. Deutsche Apotheker Zeitung 1986, 126:575-578.
22. Sherr J. Dynamics and Methodology of Homeopathic Provings 1994, London: Dynamis School.
23. Walach H, Kösters H, Henning T, Haag G. The effects of homeopathic belladonna 30 CH in healthy volunteers - a randomised, double blind experiment. J Psychosom Res 2001, 50:155-160. 10.1016/S0022-3999(00)00224-5, 11316508.
24. Häuser W, Hansen E, Enck P. Nocebo phenomena in medicine: their relevance in everyday clinical practice. Dtsch Arztebl Int 2012, 109:459-465. 3401955, 22833756.
25. Klosterhalfen S, Kellermann S, Braun S, Kowalski A, Schrauth M, Zipfel S, Enck P. Gender and the nocebo response following conditioning and expectancy. J Psychosom Res 2009, 66:323-328. 10.1016/j.jpsychores.2008.09.019, 19302890.
26. Rief W, Nestoriuc Y, von Lilienfeld-Toal A, Dogan I, Schreiber F, Hoffmann SG, Barsky AJ, Avorn J. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf 2009, 32:1041-1056. 10.2165/11316580-000000000-00000, 19810776.
27. Bayr G. A model for homeopathic drug tests including statistical analysis. Br Homeopath J 1986, 75:80-88.
28. Mitsikostas DD, Mantonakis LI, Chalarakis NG. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment of headaches. Cephalgia 2011, 31:550-561.
29. Häuser W, Bartram C, Bartram-Wunn E, Tölle T. Adverse events attributable to nocebo in randomised controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: a systematic review. Clin J Pain 2012, 28:437-451. 10.1097/AJP.0b013e3182321ad8, 22336767.
30. Mora MS, Nestoriuc Y, Rief W. Lessons learned from placebo groups in antidepressant trials. Philos Trans R Soc Lond B Biol Sci 2011, 366:1879-1888. 10.1098/rstb.2010.0394, 3130402, 21576145.
31. Amanzio M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009, 146:261-269. 10.1016/j.pain.2009.07.010, 19781854.
32. Link J, Haggard R, Kelly K, Forrer D. Placebo/nocebo symptom reporting in a sham herbal supplement trial. Eval Health Prof 2006, 29:394-406. 10.1177/0163278706293403, 17102062.